Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

NCT02949570 is registered in ClinicalTrials.gov with Hybrigenics Corporation as lead sponsor.

NCT NCT02949570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02949570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
Lead sponsor
Hybrigenics Corporation
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2014
Completion date
April 30, 2018
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cml, chronic phase